Research programme: haemoglobin hyperpolymers - Sangui BioTech

Drug Profile

Research programme: haemoglobin hyperpolymers - Sangui BioTech

Alternative Names: SBT-102

Latest Information Update: 08 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangui BioTech International
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory distress syndrome; Septic shock

Most Recent Events

  • 24 Sep 2014 Sangui BioTech has patent protection for Artificial oxygen carriers in USA, Germany, France, Great Britain, Ita­ly and Spain (Sangui BioTech, From 10-K, September 2014)
  • 01 Jun 2014 Preclinical trials in Respiratory distress syndrome in USA (Intraperitonial) (Sangui BioTech, Form 10-K, September 2014)
  • 01 Jun 2014 Preclinical trials in Septic shock in USA (Intraperitonial) (Sangui BioTech, Form 10-K, September 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top